Ginkgo Bioworks Holdings (DNA) Receivables - Other (2021 - 2025)

Ginkgo Bioworks Holdings has reported Receivables - Other for 5 years, with the latest figure at $11.2 million in Q3 2025.

• For the quarter ending Q3 2025, Receivables - Other rose 38.27% year-over-year to $11.2 million; the trailing twelve-month figure through Sep 2025 stood at $11.2 million (up 38.27% YoY), and the FY2023 full-year result was $10.1 million, up 547.02% from the prior year.
• Receivables - Other for Q3 2025 stood at $11.2 million, up from $10.9 million in the prior quarter.
• The five-year high for Receivables - Other was $11.2 million in Q3 2025, with the low at $300000.0 in Q2 2021.
• Historically, Receivables - Other has averaged $6.3 million across 5 years, with a median of $6.5 million in 2022.
• The largest YoY upside for Receivables - Other was 2066.67% in 2022 against a maximum downside of 65.37% in 2022.
• Ginkgo Bioworks Holdings' Receivables - Other stood at $6.0 million in 2021, then sank by 65.37% to $2.1 million in 2022, then surged by 382.1% to $10.1 million in 2023, then retreated by 19.8% to $8.1 million in 2024, then surged by 38.27% to $11.2 million in 2025.
• The last three Receivables - Other figures came in at $11.2 million (Q3 2025), $10.9 million (Q2 2025), and $8.1 million (Q3 2024), per Business Quant data.